OakChart

Apyx Medical Corp

APYXHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 2:15 PM ET

2.95+0.02 (0.68%)
2026-11-11 20:16 CET
Market cap
123.42 USD m
Revenue, TTM
59.57 USD m
Net income, TTM
-8.44 USD m
Free cash flow, TTM
-8.89 USD m
EPS diluted, TTM
-0.19
P/E
-
Compare

Price

APYX against its 20, 50 and 200-day averages
2050200beat
3.004.005.00497K995KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26APYXclose 2.9520-day 2.6450-day 2.73200-day 3.562.9552w high52w low

41.9% under the 52-week high of 5.08 on 9 Jun 2026. 52-week low 2.25 on 23 Oct 2026. Last 15 sessions, 46.7% high to low

Profile

APYX
52-week range, 25% of the way up
2.255.08

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used by the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Surgical Aesthetics and Original Equipment Manufacturer (OEM). The Surgical Aesthetics segment consists of the Helium Plasma Technology lines, which include Renuvion and J-Plasma. The OEM segment focuses on designing, development, and manufacturing electrosurgical equipment and medical devices by producing generators, medical devices and related accessories. The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

Employees205
IPOFeb 22, 1999
Beta1.44
ATR, 14d0.20
Rel volume0.18
Short float0.67%
Insider own13.56%
Inst own53.90%

Snapshot

6 groups

Valuation

Index-
Market Cap124.26M
Enterprise Value138.64M
Income-8.44M
Sales59.57M
Book/sh0.23
Cash/sh0.61
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees205
IPOFeb 22, 1999

Ratios

P/E-
Forward P/E-
PEG-
P/S2.09
P/B12.90
P/C4.82
P/FCF-
EV/EBITDA-
EV/Sales2.33
Quick Ratio3.85
Current Ratio4.95
Debt/Eq4.13
LT Debt/Eq4.08
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.19
EPS next Y-0.19
EPS next Q-0.04
EPS this Y25.31%
EPS next Y5.79%
EPS next 5Y31.97%
EPS past 3/5Y25.94% 4.74%
Sales past 3/5Y5.89% 13.78%
EPS Y/Y TTM46.90%
Sales Y/Y TTM24.35%
EPS Q/Q16.84%
Sales Q/Q8.95%
EarningsNov 05 BMO
EPS/Sales Surpr.57.13% 5.61%

Ownership

Insider Own13.56%
Insider Trans0.00%
Inst Own53.90%
Inst Trans6.78%
ROA-14.17%
ROE-108.99%
ROIC-17.25%
Gross Margin38.45%
Oper. Margin-5.50%
Profit Margin-14.16%
SMA2011.91%
SMA508.02%
SMA200-17.03%
Trades-

Technical

Shs Outstand42.12M
Shs Float36.41M
Short Float0.67%
Short Ratio1.61
Short Interest0.25M
52W High5.08 -41.93%
52W Low2.25 31.11%
Volatility10.51% 7.08%
ATR (14)0.20
RSI (14)61.22
Beta1.44
Rel Volume0.18
Avg Volume152.75K
Volume20,421

Performance

Perf Week13.90%
Perf Month13.46%
Perf Quarter-2.96%
Perf Half Y-23.18%
Perf YTD-15.71%
Perf Year-26.25%
Perf 3Y68.09%
Perf 5Y-79.79%
Perf 10Y-25.69%
Recom1.00
Target Price6.50
Prev Close2.93
Price2.95
Change %0.68%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Sep 29, 2026InitiatedMMaxim GroupBuy$6+103.4%
Jul 13, 2026InitiatedHH.C. WainwrightBuy$7+137.3%
Mar 11, 2026UpgradeBBTIG ResearchNeutral → Buy$6+103.4%
Dec 16, 2025InitiatedRRoth CapitalBuy$6+103.4%
Nov 14, 2025UpgradeCCitizens JMPMkt Perform → Mkt Outperform
Nov 12, 2025UpgradeCCitizens JMPMkt Perform → Mkt Outperform$8+171.2%
Oct 17, 2024InitiatedBBTIG ResearchNeutral
Jul 14, 2023InitiatedSStephensOverweight$8+171.2%
May 20, 2022InitiatedLLake StreetBuy$12+306.8%
Apr 02, 2019ReiteratedDDougherty & CompanyBuy$12 → $9+205.1%

Peers

Mkt cap
TickerCompanyMkt cap
INMDInmode Ltd781.45M
SRTSSensus Healthcare Inc56.30M
CNMDConmed Corp1.52B
ESTAEstablishment Labs Holdings Inc2.11B
PLSEPulse Biosciences Inc4.12B
LNSRLENSAR Inc53.81M
SNWVSanuwave Health Inc14.23M
EOLSEvolus Inc485.82M
AIRSAirsculpt Technologies Inc62.26M
IRIXIRIDEX Corp12.78M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Waldman LawrenceDirectorJun 30 '26Option Exercise1.8812,00022,56017,338Jul 02 05:00 PM
Roman Shawn DavidChief Operating OfficerJun 15 '26Option Exercise3.2315,00048,45015,000Jun 17 05:15 PM
CITRONOWICZ MOSHESenior Vice PresidentMar 15 '26Option Exercise1.8037,00066,600493,504Mar 17 06:27 PM
Roman Shawn DavidChief Operating OfficerJan 27 '26Option Exercise1.8012,00021,60012,000Jan 29 05:21 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B

News

latest 14 of 200
  • Apyx Medical Beats On A Narrower Loss And Positive EBITDA, But Revenue Growth Slows Sharply To Single Digits (Earnings Whispers) +18.15%
  • Apyx: Q3 Earnings Snapshot (Associated Press)
  • Apyx Medical Corporation Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Apyx Faces Power Liposuction Launch Test After Shares Slump 40% Since Last Report (Earnings Whispers)
  • Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 (GlobeNewswire)
  • Apyx Medical Corporation to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Apyx Medical Announces New Clinical Study Demonstrating Renuvion's Impact on Skin Quality (GlobeNewswire)
  • Apyx Medical Corp (APYX) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% on Power Lipo ... (GuruFocus.com)
  • Apyx Medical Corporation Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
  • Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 (GlobeNewswire)
  • Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway (PR Newswire)
  • New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Aveli and Renuvion (GlobeNewswire) +12.14%
  • Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion Used in Combination with Liposuction (GlobeNewswire) +13.54%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.040-0.093-0.04014.0313.296
2026Q22026-08-06-0.070-0.082-0.07413.8813.185
2026Q12026-05-07-0.050-0.110-0.04812.4910.534
2025Q42026-03-10-0.030-0.055-0.03119.1618.545
2025Q32025-11-06-0.050-0.102-0.04912.8812.004
2025Q22025-08-07-0.090-0.093-0.09311.3711.703
2025Q12025-05-08-0.100-0.120-0.1029.439.393
2024Q42025-03-13-0.120-0.160-0.12114.2213.394
2024Q32024-11-08-0.140-0.184-0.13611.4911.385
2024Q22024-08-08-0.190-0.198-0.18912.1511.755
2024Q12024-05-09-0.220-0.216-0.21910.249.535
2023Q42024-03-21-0.280-0.178-0.27714.6614.855
2023Q32023-11-09-0.130-0.114-0.13411.9815.375
2023Q22023-08-10-0.030-0.070-0.02913.5714.335
2023Q12023-05-11-0.100-0.135-0.10112.1410.844
2022Q42023-03-16-0.170-0.143-0.17512.6112.944

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-0.176-0.180-0.16738.8837.35
2018FY1.8601.870-0.17116.6916.72
2019FY-0.580-0.595-0.57828.1527.71
2020FY-0.350-0.413-0.34827.7126.50
2021FY-0.440-0.495-0.44248.5246.32
2022FY-0.670-0.640-0.67244.5144.84
2023FY-0.540-0.444-0.54152.3552.53
2024FY-0.660-0.705-0.66048.1047.28
2025FY-0.270-0.303-0.27052.8452.22
2026FY--0.202--59.60
2027FY--0.190--65.81
2028FY--0.085--75.86

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0560519.1919.1019.38
2026Q4S2026-10-2160019.7319.3820.08
2026Q4S2026-10-0961319.7319.3820.08
2026Q4S2026-09-2861319.7419.3820.08
2026Q4S2026-08-0751319.7619.3820.08
2026Q4S2026-07-2150020.1919.4020.62
2026Q4S2026-07-1050220.1919.4020.62
2026Q4S2026-05-2440220.0919.3820.62
2026Q4S2026-05-1541220.0919.3820.62
2026Q4S2026-05-0741220.0919.4020.62
2026Q4S2026-05-0643020.2819.4020.97
2026Q4S2026-04-1053119.9618.7020.97
2026Q4S2026-03-2553119.9618.7020.97
2026Q4S2026-03-1754119.9618.7020.97

Estimate history

EPS, annual-0.167-0.171-0.578-0.348-0.442-0.672-0.541-0.66-0.273-0.1935
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.136-0.121-0.102-0.093-0.049-0.031-0.048-0.074-0.041
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual10.23416.60528.23527.71148.51744.5152.34948.10252.84459.57
Period201720182019202020212022202320242025TTM
Sales, quarterly11.48714.2229.4311.37312.87719.16412.4913.88414.03
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual32.87833.70534.1734.28934.4134.59834.64437.79441.78642.124
Period201720182019202020212022202320242025MRQ
Shares, quarterly34.64437.79437.79437.79437.81941.78641.86842.11642.124
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue59.5752.8448.1052.3544.5148.5227.7128.2316.61
Cost of Goods Sold Incl. D&A36.6633.8136.0938.2334.0032.4425.0223.2215.32
Gross Profit22.9119.0312.0114.1210.5116.082.695.011.28
Selling, General and Administrative Excl. Other26.1825.4830.8534.0734.0730.5322.7725.8814.82
Research and Development3.353.375.084.844.544.323.923.732.55
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-3.28-6.45-18.84-19.95-23.56-14.45-20.08-20.87-13.54
Interest Expense5.585.595.912.480.010.010.050.010.10
Unusual Expense0.000.000.003.090.000.000.000.000.72
Net Income Before Taxes-7.78-10.84-23.31-21.28-22.91-14.82-19.41-19.84-14.69
Income Taxes0.480.270.25-2.430.370.38-7.50-0.13-3.91
Consolidated Net Income-8.26-11.11-23.56-18.85-23.28-15.20-11.91-19.71-10.78
Net Income From Continuing Operations-8.44-11.21-23.46-18.71-23.18-15.17-11.90-19.71-10.78
Net Income-8.44-11.21-23.46-18.71-23.18-15.17-11.90-19.71-5.68
EPS (Recurring)-0.19-0.27-0.66-0.48-0.67-0.44-0.35-0.58-0.15
EPS (Basic, Before Extraordinaries)-0.19-0.27-0.66-0.54-0.67-0.44-0.35-0.58-0.17
EPS (Diluted)-0.19-0.27-0.66-0.54-0.67-0.44-0.35-0.58-0.17
EBITDA-2.47-5.79-18.25-19.26-22.67-13.54-19.20-20.11-12.87
Non-Operating Income (Expense)1.081.201.454.240.67-0.360.721.04-0.33
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.081.583.175.115.295.093.072.611.76
Price To Sales Ratio1.812.721.171.731.819.078.8910.2113.41
Gross Margin38.4536.0224.9626.9823.6133.149.7017.767.74
Operating Margin-5.50-12.20-39.18-38.11-52.94-29.78-72.47-73.91-81.51
Net Margin-14.16-21.22-48.78-35.75-52.09-31.27-42.93-69.79-34.24
Shares Outstanding42.1241.7937.7934.6434.6034.4134.2934.1733.70
Market Capitalization123.42123.4259.4890.7780.96440.29246.78289.06284.28

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue14.0313.8812.4919.1612.8811.379.4314.22
Cost of Goods Sold Incl. D&A8.628.397.8211.837.777.366.859.72
Gross Profit5.415.504.677.335.114.012.584.50
Selling, General and Administrative Excl. Other5.987.305.587.325.946.585.637.54
Research and Development0.850.790.770.940.800.820.801.12
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.57-1.81-0.910.01-0.83-2.57-3.05-3.05
Interest Expense1.411.391.371.411.411.391.381.65
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-1.69-2.95-2.00-1.15-1.88-3.69-4.12-4.57
Income Taxes0.120.120.140.090.080.050.050.09
Consolidated Net Income-1.81-3.07-2.14-1.24-1.96-3.74-4.17-4.66
Net Income From Continuing Operations-1.78-3.24-2.11-1.30-1.98-3.78-4.15-4.63
Net Income-1.78-3.24-2.11-1.30-1.98-3.78-4.15-4.63
EPS (Recurring)-0.04-0.07-0.05-0.03-0.05-0.09-0.10-0.12
EPS (Basic, Before Extraordinaries)-0.04-0.07-0.05-0.03-0.05-0.09-0.10-0.12
EPS (Diluted)-0.04-0.07-0.05-0.03-0.05-0.09-0.10-0.12
EBITDA-0.38-1.61-0.710.23-0.67-2.44-2.91-2.91
Non-Operating Income (Expense)0.290.250.280.250.370.280.300.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.590.850.250.400.420.410.360.66
Price To Sales Ratio1.813.372.892.791.821.971.181.26
Gross Margin38.5339.5937.4138.2639.6535.2727.4031.62
Operating Margin-4.07-13.01-7.290.06-6.46-22.63-32.35-21.43
Net Margin-12.72-23.36-16.88-6.78-15.41-33.22-44.01-32.54
Shares Outstanding42.1242.1241.8741.7937.8237.7937.7937.79
Market Capitalization123.42188.01154.35143.6080.9385.0451.7859.48

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments31.7431.7443.6510.1930.8741.9158.8178.2710.67
Short Term Receivables16.7815.4814.0518.2521.1617.339.225.084.86
Inventories8.607.569.9211.806.784.055.073.154.27
Other Current Assets1.351.662.732.741.932.793.633.332.75
Total Current Assets58.4756.4470.3642.9760.7466.0976.7389.8322.55
Net Property, Plant & Equipment6.626.747.157.596.877.217.625.796.03
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-------0.190.25
Deferred Tax Assets-------0.150.19
Other Assets1.751.661.731.221.110.810.390.302.16
Total Assets66.8464.8479.2451.7768.7274.1184.7595.9331.18
Short Term Debt Incl. Current Port. of LT Debt0.430.350.370.250.290.360.480.000.24
Accounts Payable3.062.622.712.672.631.512.441.421.58
Other Current Liabilities8.217.759.668.9310.297.289.407.194.15
Total Current Liabilities11.7010.7212.7411.8513.219.1512.318.615.97
Long Term Debt38.9138.4138.130.540.020.310.660.142.60
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-------0.150.56
Other Liabilities1.401.381.441.591.490.790.520.000.02
Total Liabilities52.0150.5152.3213.9814.7110.2513.498.759.14
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity14.5414.2126.7037.5853.7063.7271.2687.1822.03
Total Shareholders Equity14.5414.2126.7037.5853.7063.7271.2687.1822.03
Accumulated Minority Interest0.290.120.220.210.300.140.000.000.00
Total Equity14.8314.3426.9237.7954.0163.8671.2687.1822.03
Total Liabilities & Stockholders Equity66.8464.8479.2451.7768.7274.1184.7595.9331.18
Book Value Per Share0.350.380.771.091.561.862.092.590.67
Tangible Book Value Per Share0.350.380.771.091.561.862.092.590.66
Full-Time Employees205220252276272266266222211
Price to Book Ratio12.824.962.721.938.213.874.063.68-
Return on Assets-17.03-32.57-28.57-38.48-21.24-14.98-21.83-16.97-41.28
Return on Equity-77.99-114.70-58.22-50.79-25.84-17.63-24.78-19.75-56.71
Return on Invested Capital-20.97-44.59-28.86-60.81-28.24-18.58-27.40-6.51-20.55
Quick Ratio4.264.564.742.634.096.785.8210.073.06
Current Ratio5.005.265.523.634.607.226.2310.433.77

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-8.26-11.11-23.56-18.85-23.28-15.20-11.91-19.7162.72
Depreciation0.810.660.600.690.890.900.890.750.67
Other Funds (Non Cash)4.474.046.157.377.335.695.213.80-66.22
Funds from Operations-2.98-6.41-16.81-10.79-15.06-8.61-5.81-15.16-3.20
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.24-1.59-1.255.54-5.22-1.84-10.25-3.32-17.68
Cash from Operating Activities-8.23-8.00-18.06-5.25-20.28-10.45-16.07-18.48-20.88
Capital Expenditures-0.67-1.11-0.72-0.53-1.01-0.72-0.58-1.30-0.36
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.060.007.410.000.200.000.0091.09
Purchase or Sale of Investments0.000.000.000.000.000.000.0061.84-61.43
Purchase of Investments0.000.000.000.000.000.000.00-18.88-87.19
Sale Or Maturity of Investments0.000.000.000.000.000.000.0080.7325.76
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.67-1.05-0.726.88-1.01-0.53-0.5860.5429.30
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock9.589.546.782.720.360.070.150.210.20
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock9.589.546.782.720.360.070.150.210.20
Proceedsfrom Stock Options9.059.056.780.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.02-0.02-0.0229.30-0.15-0.24-0.37-0.06-2.69
Change in Long Term Debt-0.02-0.02-0.0229.30-0.15-0.24-0.37-0.06-2.69
Issuance of Long Term Debt0.000.000.0040.370.000.000.000.000.00
Reduction of Long Term Debt-0.02-0.02-0.02-11.07-0.15-0.24-0.37-0.06-2.69
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.150.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities9.569.526.7632.020.22-0.17-0.070.15-2.49
Exchange Rate Effect-0.02-0.470.11-0.190.400.10-0.180.000.00
Net Change in Cash0.64-0.00-11.9133.46-20.68-11.04-16.9042.225.93
Free Cash Flow-8.89-9.12-18.78-5.78-21.29-11.17-16.65-19.78-21.24
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00-0.37

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments25.7827.6231.1431.7425.1429.30
Short Term Receivables14.8713.6112.7616.7812.9911.25
Inventories11.9510.759.548.609.148.19
Other Current Assets1.241.181.371.351.511.17
Total Current Assets53.8453.1654.8058.4748.7949.91
Net Property, Plant & Equipment6.086.146.356.626.766.55
Total Investments and Advances0.000.000.000.000.000.00
Other Assets1.741.781.881.751.811.72
Total Assets61.6761.0763.0266.8457.3758.19
Short Term Debt Incl. Current Port. of LT Debt0.480.470.440.430.410.40
Accounts Payable3.512.192.633.063.222.89
Other Current Liabilities6.876.696.388.217.347.28
Total Current Liabilities10.879.359.4511.7010.9810.57
Long Term Debt39.2639.1639.0238.9138.8038.68
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.501.471.471.401.511.49
Total Liabilities51.6349.9849.9452.0151.2850.73
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity9.6310.6612.8314.545.857.25
Total Shareholders Equity9.6310.6612.8314.545.857.25
Accumulated Minority Interest0.410.430.260.290.230.20
Total Equity10.0411.0913.0914.836.087.46
Total Liabilities & Stockholders Equity61.6761.0763.0266.8457.3758.19
Book Value Per Share0.230.250.310.350.150.19
Tangible Book Value Per Share0.230.250.310.350.150.19
Full-Time Employees---205--
Price to Book Ratio12.8214.6510.6022.6311.158.09
Return on Assets-14.17-14.48-14.89-17.03-24.63-27.93
Return on Equity-108.99-96.38-78.56-77.99-172.18-156.90
Return on Invested Capital-3.65-6.51-4.07-2.43-4.44-8.23
Quick Ratio3.854.534.794.263.613.95
Current Ratio4.955.685.805.004.444.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-1.81-3.07-2.14-1.24-1.96-3.74
Depreciation0.190.200.200.220.160.13
Other Funds (Non Cash)1.171.470.581.250.971.08
Funds from Operations-0.45-1.41-1.360.23-0.82-2.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.19-2.080.79-2.76-2.721.29
Cash from Operating Activities-1.63-3.49-0.57-2.53-3.54-1.23
Capital Expenditures-0.27-0.07-0.06-0.28-0.52-0.27
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.03
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.00-
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.27-0.07-0.06-0.28-0.52-0.23
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.099.490.050.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.099.490.050.00
Proceedsfrom Stock Options0.000.000.009.050.000.00
Issuance or Reduction of Debt, Net-0.01-0.01-0.01-0.01-0.00-0.01
Change in Long Term Debt-0.01-0.01-0.01-0.01-0.00-0.01
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.01-0.01-0.01-0.00-0.01
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.01-0.010.089.480.04-0.01
Exchange Rate Effect0.060.04-0.05-0.07-0.16-0.24
Net Change in Cash-1.84-3.52-0.606.61-4.17-1.71
Free Cash Flow-1.90-3.56-0.63-2.81-4.05-1.50

Revenue breakdown

Non-US2024: 14.08M 2025: 14.04M
United States2024: 34.02M 2025: 38.80M
OEM2024: 9.50M 2025: 7.51M
Surgical Aesthetics2024: 38.61M 2025: 45.33M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.67%0.2M36.4M141.62K
2026-10-150.59%0.2M36.4M129.97K
2026-09-300.57%0.2M36.4M121.34K
2026-09-150.60%0.2M36.4M113.03K
2026-08-310.56%0.2M36.4M131.61K
2026-08-140.63%0.2M36.4M124.49K
2026-07-310.73%0.3M36.4M159.06K
2026-07-150.70%0.3M36.2M170.44K
2026-06-300.49%0.2M36.2M177.59K
2026-06-150.39%0.1M35.9M175.84K
2026-05-290.58%0.2M36.3M170.04K
2026-05-150.46%0.2M36.3M163.13K
2026-04-300.61%0.2M36.3M128.39K
2026-04-150.54%0.2M36.3M133.66K
2026-03-310.53%0.2M36.1M134.45K
2026-03-130.46%0.2M36.1M117.92K
2026-02-270.49%0.2M35.4M101.06K
2026-02-130.40%0.1M35.4M118.09K
2026-01-300.36%0.1M35.4M118.62K
2026-01-150.32%0.1M35.4M104.83K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.450.550.451.6794.000.000.736-0.0190.001
call5.000.000.250.103.97522.000.000.292-0.0350.002
call7.500.000.100.294.1752.000.000.134-0.0230.001
put2.500.050.200.072.24744.0010.00-0.264-0.0190.001
put5.002.002.102.052.7641.000.00-0.708-0.0350.002
put7.504.504.600.004.5350.000.00-0.866-0.0220.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-28SCHEDULE 13GSEC
2026-09-298-KCurrent report2026-09-29SEC
2026-08-078-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-248-KCurrent report2026-07-24SEC
2026-07-21SCHEDULE 13G/ASEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-26DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-31SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-178-KCurrent report2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-01SDSpecialized Disclosure ReportSEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-03-174Statement of changes in beneficial ownership of securities2026-03-15SEC
2026-03-1010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-108-KCurrent report2026-03-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC15.62%
ROYCE & ASSOCIATES LP8.32%
Archon Capital Management LLC6.32%
VANGUARD CAPITAL MANAGEMENT LLC3.67%
AIGH Capital Management LLC2.68%
ESSEX INVESTMENT MANAGEMENT CO LLC2.62%
Silverberg Bernstein Capital Management LLC2.43%
COMMONWEALTH EQUITY SERVICES, LLC1.55%
HORIZON KINETICS ASSET MANAGEMENT LLC1.40%
BlackRock, Inc.1.34%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.62%
ROYCE MICRO-CAP TRUST, INC.2.32%
Royce Small-Cap Opportunity Fund1.67%
Royce Micro-Cap Fund1.40%
RENN Fund, Inc.1.40%
VANGUARD EXTENDED MARKET INDEX FUND0.95%
1290 Essex Small Cap Growth Fund0.66%
Royce Capital Fund - Micro-Cap Portfolio0.51%
Fidelity Extended Market Index Fund0.42%
Taylor Frigon Core Growth Fund0.30%

OakChart. APYX. Cached 15 minutes.